Metrics as of 10/17/2026, 04:58 AM (Berlin time), refresh in progress.
Apogee Therapeutics Stock
Apogee Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Thomas Henderson
- Employees
- 261
- Market cap
- $8.4 B
- IPO
- 14/07/2023
Apogee Therapeutics, Inc. is a biotechnology company in the healthcare sector, headquartered in Waltham, US. Founded in 2022, the firm operates through its subsidiary and focuses on advancing biologic treatments for various conditions, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Apogee Therapeutics stock: price history
1D
-0.0%
1W
+0.1%
1M
+0.7%
6M
+86.8%
YTD
+78.9%
1Y
+256.8%
2Y
+164.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~31% stronger price swings than usual
Apogee Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 30/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Apogee Therapeutics is a biotechnology company focused on developing biologic therapeutics for the treatment of inflammatory and immune diseases. The pipeline centers on monoclonal antibodies such as APG777 and APG808, which through technically optimized extended half-lives in subcutaneous injections could offer application benefits for patients. The company addresses indications such as atopic dermatitis and chronic obstructive pulmonary disease through various drug candidates in development.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Apogee Therapeutics
Analyst assessment of Apogee Therapeutics
PRICE TARGET LOW
US$89.00
CONSENSUS
US$130.92
MEDIAN
US$135.00
PRICE TARGET HIGH
US$140.00
0
STRONG BUY
2
BUY
12
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Hold
As of: 13/08/2026
Apogee Therapeutics stock metrics
P/E
-31.12
P/B
8.53
EV/EBITDA
-28.54
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.4%
FLOAT SHARES
57,171,166
AVG. DAILY VOLUME (30D)
1,335,967
Insider transactions (SEC)
Fairmount Funds Management LLC
McKenna Mark C.
JONES WILLIAM A JR
Dambkowski Carl
Dambkowski Carl
Institutional holders
Comparable stocks
Frequently asked questions about Apogee Therapeutics stock
What does Apogee Therapeutics do?
Apogee Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Thomas Henderson, the company employs around 261 people.
The IPO was on 14/07/2023; the stock trades on NASDAQ under the ticker APGE.
What do analysts say about Apogee Therapeutics stock?
14 analysts rate the stock, the consensus is Hold (as of 13/08/2026).
The average price target is US$130.92, ranging from US$89.00 to US$140.00, with a median of US$135.00.
This is an external assessment, not a statement by Market Jury.
When does Apogee Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does Apogee Therapeutics pay a dividend?
No, Apogee Therapeutics currently does not pay a dividend.
Which stocks are comparable to Apogee Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Apogee Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Apogee Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.